Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Kintor Pharmaceutical Ltd ( (HK:9939) ) is now available.
Kintor Pharmaceutical Limited announced that its Phase II clinical trial of GT20029 gel for treating acne in China has successfully met its primary endpoint, demonstrating significant efficacy, safety, and pharmacokinetics. The trial, which involved 10 clinical research centers in China, showed that GT20029 gel has the potential to become a new generation treatment for acne vulgaris and androgenetic alopecia. The company plans to initiate a Phase III clinical trial in China to further leverage its first-mover advantage in topical PROTAC compounds.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a clinical-stage novel drug developer specializing in dermatology, focusing on creating potential first-in-class and best-in-class drugs. The company is also expanding into the functional cosmetics area to address unmet clinical and consumer needs, aiming to lead in the research, development, and commercialization of innovative therapies and high-end cosmetics.
Average Trading Volume: 6,254,586
Technical Sentiment Signal: Buy
Current Market Cap: HK$911.4M
Find detailed analytics on 9939 stock on TipRanks’ Stock Analysis page.